ALPMY (Astellas Pharma) Ending Cash Position : $57 Mil (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Ending Cash Position?

Astellas Pharma's Ending Cash Position for the quarter that ended in Mar. 2025 was $57 Mil.

Astellas Pharma's quarterly Ending Cash Position declined from Sep. 2024 ($2,050 Mil) to Dec. 2024 ($1,169 Mil) and declined from Dec. 2024 ($1,169 Mil) to Mar. 2025 ($57 Mil).

Astellas Pharma's annual Ending Cash Position declined from Mar. 2023 ($2,819 Mil) to Mar. 2024 ($2,241 Mil) and declined from Mar. 2024 ($2,241 Mil) to Mar. 2025 ($1,264 Mil).

Astellas Pharma Ending Cash Position Historical Data

The historical data trend for Astellas Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Ending Cash Position Chart

Astellas Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Ending Cash Position

Get a 7-Day Free Trial

3,000.28

2,664.81

2,819.30

2,240.62

1,263.75

Astellas Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															2,240.62	1,918.97	2,049.56	1,169.37	57.07

Astellas Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Astellas Pharma's Ending Cash Position for the fiscal year that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2252.056	+	-988.303
	=	1,264

Astellas Pharma's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	-1.4210854715202E-14	+	57.072
	=	57

Astellas Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.